Newsletter | March 27, 2025

03.27.25 -- How Is The Market Responding To Brisk HPAPI Demand?

SPONSOR

Webinar: Minimizing your Risk in RNA-lipid Nanoparticle (LNP) Encapsulation and Drug Product Manufacturing Through a Holistic Approach

Join us on March 31st to discover how Lonza's platform-based strategy ensures stability, efficacy, and quality in LNP Drug Products with nucleic acid payloads. Learn about critical process challenges in encapsulation, filtration, and aseptic filling, and how to proactively mitigate risks for successful GMP batch manufacturing. Register now for expert insights! Click here to learn more.

FOCUS ON OUTSOURCING

How Is The Market Responding To Brisk HPAPI Demand?

By Pooja Sharma, Global Market Insights

The rise of precision medicine like ADCs has created new markets for highly potent API. More suppliers are building out capacity to meet the demand.

The Stage-Gate Model: A Proven Approach To Streamline Biomanufacturing

White Paper | Resilience US, Inc.

Learn how a Stage-Gate approach to technology transfer and biomanufacturing can help to mitigate risk while shortening cycle times throughout the project lifecycle.

5 Trends Impacting CMOs In 2025

Article | Jubilant HollisterStier

In 2025, CMOs will navigate Annex 1 compliance, the BioSecure Act’s uncertainty, AI-driven drug development, supply chain challenges from tariffs, and pandemic preparedness strategies.

The Potential Of Intensified Scalable Adherent Cell Culture — Part 2

Q&A | By Junwei Sun, Dr. Lucia Fernandez, and Matthew Ercolino, VintaBio

Intensified adherent cell culture offers a promising solution to the limitations of traditional suspension culture, with the potential to improve efficiency, reduce costs, and accelerate development.

Rapid Developability Assessments To Assist Lead Candidate Selection

Poster | By Robert Cunningham, Judit Csapo, Emily Mallett, Marta Busse, et al., Abzena

Uncover how rapid, multidimensional assessments that optimize stability, manufacturability, and clinical success potential have been able to accelerate lead candidate selection.

Microbial Biomanufacturing: Where We've Been And Where We Are Going

Article | Cytovance Biologics

Learn more about the cutting-edge technologies driving the shift to microbial expression and how the right outsourcing partner can help you leverage the benefits of these innovative therapeutics.

Small Is Powerful And Sustained

Article | Nanoform

Advances in sustained-release drug delivery could improve efficiency and consistency in drug release, manifesting real-life advantages for patients in the form of enhanced accessibility and compliance.

SPONSOR

The debate rages on. While the automation that enables continuous processing gets a lot of hype, there are plenty of dyed-in-the-wool biopharma pros who contend that process optimization and intensification yield comparable benefits, without requiring the capital-intensive process overhaul that continuous demands. Join Bioprocess Online Live for a virtual deep dive into the scalability, sustainability, and capital implications of the continuous-versus-optimized debate. Registration is free thanks to the support of Cytiva.

OUTSOURCING SOLUTIONS

•

Choosing A CDMO With Capacity Designed For You - INCOG BioPharma Services

•

Capacity Update January 2025: Fill/Finish - Ajinomoto Bio-Pharma Services

•

mRNA/LNP Development And Manufacturing Services - Lonza

•

Cell Line Characterization Testing Package - WuXi Advanced Therapies

•

Quality Used Industrial And Process Equipment - Federal Equipment Company

Connect With Bioprocess Online: